Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13278424 | 0.87 | NPC1 (0.35) | NPC1RAB9AKDM4ELMNASMN1; SMN2 | |
| SCHEMBL14798183 | 0.82 | GABBR2 (0.36) | KDM4ELMNASMN1; SMN2 | |
| SCHEMBL1905236 | 0.81 | NPC1 (0.37) | NPC1RAB9AKDM4ELMNASMN1; SMN2 | |
| SCHEMBL6902296 | 0.81 | NPC1 (0.37) | NPC1RAB9AKDM4ELMNASMN1; SMN2 | |
| SCHEMBL1904197 | 0.81 | NPC1 (0.37) | NPC1RAB9AKDM4ELMNASMN1; SMN2 | |
| SCHEMBL13471789 | 0.80 | KDM4E (0.34) | NPC1RAB9AKDM4ELMNASMN1; SMN2 | |
| SCHEMBL1932163 | 0.79 | KDM4E (0.40) | NPC1RAB9AKDM4ELMNASMN1; SMN2 | |
| SCHEMBL1932493 | 0.79 | KDM4E (0.40) | NPC1RAB9AKDM4ELMNASMN1; SMN2 | |
| SCHEMBL1932001 | 0.79 | KDM4E (0.40) | NPC1RAB9AKDM4ELMNASMN1; SMN2 | |
| SCHEMBL13278515 | 0.79 | NPC1 (0.34) | NPC1RAB9AKDM4ELMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11377417-B2 | Branched 3-phenylpropionic acid derivatives and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2022-07-05 | — | — | US | disclosed |
| US-11377417-B2 | Branched 3-phenylpropionic acid derivatives and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2022-07-05 | — | — | US | disclosed |
| US-20200385335-A1 | BRANCHED 3-PHENYLPROPIONIC ACID DERIVATIVES AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2020-12-10 | — | — | US | disclosed |
| US-20190185415-A1 | BRANCHED 3-PHENYLPROPIONIC ACID DERIVATIVES AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2019-06-20 | — | — | US | disclosed |
| US-10259776-B2 | Branched 3-phenylpropionic acid derivatives and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2019-04-16 | — | — | US | disclosed |
| US-10259776-B2 | Branched 3-phenylpropionic acid derivatives and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2019-04-16 | — | — | US | disclosed |
| US-20180282262-A1 | BRANCHED 3-PHENYLPROPIONIC ACID DERIVATIVES AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2018-10-04 | — | — | US | disclosed |
| US-10023528-B2 | Branched 3-phenylpropionic acid derivatives and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-07-17 | — | — | US | disclosed |
| US-10023528-B2 | Branched 3-phenylpropionic acid derivatives and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-07-17 | — | — | US | disclosed |
| US-10023528-B2 | Branched 3-phenylpropionic acid derivatives and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-07-17 | — | — | US | disclosed |
| US-20140309307-A1 | Branched 3-phenylpropionic acid derivatives and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-10-16 | — | — | US | disclosed |
| US-20140309307-A1 | Branched 3-phenylpropionic acid derivatives and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-10-16 | — | — | US | disclosed |
| US-8796335-B2 | Branched 3-phenylpropionic acid derivatives and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-08-05 | — | — | US | disclosed |
| US-8796335-B2 | Branched 3-phenylpropionic acid derivatives and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-08-05 | — | — | US | disclosed |
| EP-2697191-A1 | BRANCHED 3-PHENYLPROPIONIC ACID DERIVATIVES AND THE USE THEREOF | Bayer Intellectual Property GmbH (DE) | 2014-02-19 | — | — | EP | disclosed |
| US-20130079412-A1 | Branched 3-phenylpropionic acid derivatives and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-03-28 | — | — | US | disclosed |
| US-20130079412-A1 | Branched 3-phenylpropionic acid derivatives and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-03-28 | — | — | US | disclosed |
| US-20130079412-A1 | Branched 3-phenylpropionic acid derivatives and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-03-28 | — | — | US | disclosed |
| WO-2012139888-A1 | BRANCHED 3-PHENYLPROPIONIC ACID DERIVATIVES AND THE USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-10-18 | — | — | WO | disclosed |
| WO-2012139888-A1 | BRANCHED 3-PHENYLPROPIONIC ACID DERIVATIVES AND THE USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079412-A1 | Branched 3-phenylpropionic acid derivatives and their use | PC, FABP3, PCCA | NPC1 1146/4885RAB9A 4097/4885KDM4E 4051/4885 |
| US-11377417-B2 | Branched 3-phenylpropionic acid derivatives and their use | PC, FABP3, PCCA | NPC1 1146/4885RAB9A 4097/4885KDM4E 4051/4885 |
| US-20190185415-A1 | BRANCHED 3-PHENYLPROPIONIC ACID DERIVATIVES AND THEIR USE | PC, FABP3, PCCA | NPC1 1146/4885RAB9A 4097/4885KDM4E 4051/4885 |
| US-20140309307-A1 | Branched 3-phenylpropionic acid derivatives and their use | PC, FABP3, PCCA | NPC1 1146/4885RAB9A 4097/4885KDM4E 4051/4885 |
| US-20200385335-A1 | BRANCHED 3-PHENYLPROPIONIC ACID DERIVATIVES AND THEIR USE | PC, FABP3, PCCA | NPC1 1146/4885RAB9A 4097/4885KDM4E 4051/4885 |
| US-10259776-B2 | Branched 3-phenylpropionic acid derivatives and their use | PC, FABP3, PCCA | NPC1 1146/4885RAB9A 4097/4885KDM4E 4051/4885 |
| US-10023528-B2 | Branched 3-phenylpropionic acid derivatives and their use | PC, FABP3, PCCA | NPC1 1146/4885RAB9A 4097/4885KDM4E 4051/4885 |
| US-20180282262-A1 | BRANCHED 3-PHENYLPROPIONIC ACID DERIVATIVES AND THEIR USE | PC, FABP3, PCCA | NPC1 1146/4885RAB9A 4097/4885KDM4E 4051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.